In fact, it has been seen that patients with low CXCR4 expression in cytotoxic T lymphocytes in peripheral blood have a better efficacy to anti-PD-1 ICIs in NSCLC because probably they are receiving trafficking orders from a higher expression of CXCL12 in tumor tissue [2,11]. Here, CXCL12 is linked to neoplasm.